Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2963756/0/en/HUTCHMED-Announces-that-TAGRISSO-plus-ORPATHYS-demonstrated-high-clinically-meaningful-response-rate-in-lung-cancer-patients-with-high-levels-of-MET-overexpression-and-or-amplifica.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942477/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-ESMO-Congress-2024-and-the-2024-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib

    29 Mar 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168216&sid=2

    PHARMABIZ
    29 Mar 2024
    Share Share
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2853678/0/en/HUTCHMED-Announces-Savolitinib-sNDA-Accepted-in-China-for-Treatment-Na%C3%AFve-or-Previously-Treated-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib
    HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib

    12 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/12/2741334/0/en/HUTCHMED-Highlights-Presentation-of-Results-from-the-Phase-IIIb-Trial-of-Savolitinib-at-the-2023-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    12 Sep 2023
    Share Share
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
    HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer

    29 Aug 2023

    // PRESS RELEASE

    https://www.hutch-med.com/savolitinib-china-breakthrough-therapy-designation-for-gastric-cancer/

    PRESS RELEASE
    29 Aug 2023
    Share Share